Per-Anders Jansson, Göteborg, Avdelningen för molekylär och klinisk medicin workplace verified by Sahlgrenska Akademin on 2017-04-05

Basic information

name:
Per-Anders Jansson
profession:
Professor, överläkare
email:

Work

department:
Gothia Forum och Sahlgrenska akademin vid Göteborgs Universitet, Avd för molekylär och klinisk medic
workplace:
Gröna Stråket 12 och Wallenberglaboratoriet, våning 2/3, Bruna Stråket 16, SU/Sahlgrenska
phone number:
070-203 30 10 alt 031-342 93 04
city:
413 45 Göteborg
country:
Sverige

Qualified assistance

Lecturer

target group and cost:
Olika grupper av vårdpersonal och allmänhet.
orientation/description:
Diabetolog med inriktning mot typ 2 diabetes särskilt sjukdomens bakomliggande orsaker, dess prevention och behandling.

Tutor

target group and cost:

Forskarstuderande inom translationell medicinsk forskning.
orientation/description:
Diabetolog med klinisk experimentell forskningsprofil inom insulinresistensområdet.

Article - Review (2)

  1. Boesgaard TW, Gjesing AP, Grarup N, Rutanen J, Jansson PA, Hribal ML, Sesti G, Fritsche A, Stefan N, Staiger H, Häring H, Smith U, Laakso M, Pedersen O, Hansen T;
    EUGENE2 Consortium.
    PLoS ONE 2009:4(9):e7236.
    Web of Science® citations 33
  2. Smith U, Axelsen M, Carvalho E, Eliasson B, Jansson PA, Wesslau C.
    Ann N Y Acad Sci. 1999:892:119-26.
    Web of Science® citations 77

Article - Peer reviewed scientific (89)

  1. Mobini R, Tremaroli V, Ståhlman M, Karlsson F, Levin M, Ljungberg M, Sohlin M, Berteus Forslund H, Perkins R, Bäckhed F, Jansson P.
    Diabetes Obesity Metabolism 2017:19(4):579-589.
    Web of Science® citations 14
  2. Fryk E, Sundelin JP, Strindberg L, Pereira MJ, Federici M, Marx N, Nyström FH, Schmelz M, Svensson PA, Eriksson JW, Borén J, Jansson PA.
    Metab Clin Exp. 2016:65(7):998-1006.
    Web of Science® citations 3
  3. Dayeh T, Tuomi T, Almgren P, Perfilyev A, Jansson PA, de Mello VD, Pihlajamäki J, Vaag A, Groop L, Nilsson E, Ling C.
    Epigenetics 2016:11(7):482-8.
    Web of Science® citations 15
  4. Volkov P, Olsson A, Gillberg L, Jorgensen S, Brons C, Eriksson K, Groop L, Jansson P, Nilsson E, Ronn T, Vaag A, Ling C.
    Plos One 2016:11(6)
    Web of Science® citations 23
  5. Daka B, Langer RD, Larsson CA, Rosén T, Jansson PA, Råstam L, Lindblad U.
    BMC Endocr Disord 2015:15:35.
    Web of Science® citations 15
  6. Nilsson E, Jansson P, Ling C, Perfilyev A, Volkov P, Pedersen M, Svensson M, Poulsen P, Ribel-Madsen R, Pedersen N, Almgren P, Fadista J, Rönn T, Klarlund Pedersen B, Scheele C, Vaag A.
    Diabetes 2014:63(9):2962-76.
    Web of Science® citations 130
  7. Hellgren MI, Petzold M, Berteus-Forslund H, Wedel H, Jansson PA, Lindblad U.
    Scandinavian Journal of Public Health 2014:42
    Web of Science® citations 3
  8. Daka B, Rosen T, Jansson PA, Råstam L, Larsson CA, Lindblad U.
    Endocr Connect 2013:2(1):18-22.
    Web of Science® citations 10
  9. Daka B, Rosen T, Jansson PA, Larsson CA, Råstam L, Lindblad U.
    BMC Cardiovasc Disord 2013:13:30.
    Web of Science® citations 12
  10. Ahlin S, Sjöholm K, Jacobson P, Andersson-Assarsson JC, Walley A, Tordjman J, Poitou C, Prifti E, Jansson PA, Borén J, Sjöström L, Froguel P, Bergman RN, Carlsson LM, Olsson B, Svensson PA.
    Obesity (Silver Spring) 2013:21(12):E571-6.
    Web of Science® citations 9
  11. Murdolo G, Sjöstrand M, Strindberg L, Lönnroth P, Jansson PA.
    J Clin Endocrinol Metab. 2013:98(1):245-54.
    Web of Science® citations 6
  12. Nitert MD, Dayeh T, Volkov P, Elgzyri T, Hall E, Nilsson E, Yang BT, Lang S, Parikh H, Wessman Y, Weishaupt H, Attema J, Abels M, Wierup N, Almgren P, Jansson PA, Rönn T, Hansson O, Eriksson KF, Groop L, Ling C.
    Diabetes 2012:61(12):3322-32.
    Web of Science® citations 140
  13. Svensson MK, Jansson PA, Persson AL, Sjöstrand M, Eriksson JW.
    J Clin Endocrinol Metab. 2011:96(11):E1843-7.
    Web of Science® citations 3
  14. Sandqvist M, Strindberg L, Schmelz M, Lönnroth P, Jansson PA.
    J Clin Endocrinol Metab. 2011:96(8):E1320-4.
    Web of Science® citations 20
  15. Hribal ML, Presta I, Procopio T, Marini MA, Stan A, Kuusisto J, Andreozzi F, Hammarstedt A, Jansson PA, Grarup N, Hansen T, Walker M, Stefan N, Fritsche A, Häring HU, Pedersen O, Smith U, Laakso M, Sesti G;
    EUGENE2 Consortium.
    Diabetologia 2011:54(4):795-802.
    Web of Science® citations 16
  16. Jansson P, Murdolo G, Sjögren L, Nyström B, Sjöstrand M, Strindberg L, Lönnroth P.
    DIABETOLOGIA 2010:53(10):2205-2208.
  17. Murdolo G, Herder C, Wang Z, Rose B, Schmelz M, Jansson PA.
    Am J Physiol Endocrinol Metab. 2008:295(5):E1095-105.
    Web of Science® citations 26
  18. Murdolo G, Sjöstrand M, Strindberg L, Gudbjörnsdóttir S, Lind L, Lönnroth P, Jansson PA.
    J Clin Endocrinol Metab. 2008:93(7):2764-73.
    Web of Science® citations 11
  19. Boesgaard TW, Zilinskaite J, Vänttinen M, Laakso M, Jansson PA, Hammarstedt A, Smith U, Stefan N, Fritsche A, Häring H, Hribal M, Sesti G, Zobel DP, Pedersen O, Hansen T;
    EUGENE 2 Consortium.
    Diabetologia 2008:51(5):816-20.
    Web of Science® citations 87
  20. Stancáková A, Pihlajamäki J, Kuusisto J, Stefan N, Fritsche A, Häring H, Andreozzi F, Succurro E, Sesti G, Boesgaard TW, Hansen T, Pedersen O, Jansson PA, Hammarstedt A, Smith U, Laakso M;
    EUGENE2 Consortium.
    J Clin Endocrinol Metab. 2008:93(5):1924-30.
    Web of Science® citations 49
  21. Laakso M, Zilinskaite J, Hansen T, Boesgaard TW, Vänttinen M, Stancáková A, Jansson PA, Pellmé F, Holst JJ, Kuulasmaa T, Hribal ML, Sesti G, Stefan N, Fritsche A, Häring H, Pedersen O, Smith U;
    EUGENE2 Consortium.
    Diabetologia 2008:51(3):502-11.
    Web of Science® citations 86
  22. Staiger H, Stancáková A, Zilinskaite J, Vänttinen M, Hansen T, Marini MA, Hammarstedt A, Jansson PA, Sesti G, Smith U, Pedersen O, Laakso M, Stefan N, Fritsche A, Häring HU.
    Diabetes 2008:57(2):514-7.
    Web of Science® citations 43
  23. Journal of internal medicine 2007:262(2):173-83.
    Web of Science® citations 95
  24. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB.
    N Engl J Med. 2006:354(24):2552-63.
    Web of Science® citations 826
  25. Hammarstedt A, Pihlajamäki J, Rotter Sopasakis V, Gogg S, Jansson PA, Laakso M, Smith U.
    J Clin Endocrinol Metab. 2006:91(3):1181-4.
    Web of Science® citations 122
  26. Dahlgren E, Gull B, Willén R, Sundler F, Rosén T, Jansson PA.
    Ups J Med Sci. 2005:110(3):233-6.
    Web of Science® citations 2
  27. Yang X, Jansson PA, Pellmé F, Laakso M, Smith U.
    Obes Res. 2005:13(5):813-7.
    Web of Science® citations 31
  28. Brekke HK, Jansson PA, Lenner RA.
    Diabetes Res Clin Pract. 2005:70(3):225-34.
    Web of Science® citations 26
  29. Brekke HK, Lenner RA, Taskinen MR, Månsson JE, Funahashi T, Matsuzawa Y, Jansson PA.
    Diabetes Res Clin Pract. 2005:68(1):18-28.
    Web of Science® citations 29
  30. Yang X, Jansson P, Nagaev I, Jack M, Carvalho E, Sunnerhagen K, Cam M, Cushman S, Smith U.
    Biochem Biophys Res Commun. 2004:317(4):1045-51.
    Web of Science® citations 115
  31. Ahrén B, Landin-Olsson M, Jansson P, Svensson M, Holmes D, Schweizer A.
    J Clin Endocrinol Metab 2004:89(5):2078-84.
    Web of Science® citations 497
  32. Jansson PA, Pellmé F, Hammarstedt A, Sandqvist M, Brekke H, Caidahl K, Forsberg M, Volkmann R, Carvalho E, Funahashi T, Matsuzawa Y, Wiklund O, Yang X, Taskinen MR, Smith U.
    FASEB J. 2003:17(11):1434-40.
    Web of Science® citations 79
  33. Pellmé F, Smith U, Funahashi T, Matsuzawa Y, Brekke H, Wiklund O, Taskinen MR, Jansson PA.
    Diabetes 2003:52(5):1182-6.
    Web of Science® citations 120
  34. Hammarstedt A, Jansson PA, Wesslau C, Yang X, Smith U.
    Biochem Biophys Res Commun. 2003:301(2):578-82.
    Web of Science® citations 96
  35. Bonnier M, Lönnroth P, Gudbjörnsdottir S, Attvall S, Jansson PA.
    J Intern Med. 2003:253(2):189-93.
    Web of Science® citations 6
  36. Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Båvenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D.
    Diabetes Care 2002:25(5):869-75.
    Web of Science® citations 325
  37. Axelsson T, Jansson P, Smith U, Eliasson B.
    J Intern Med 2001:249(6):539-44.
    Web of Science® citations 36
  38. Carvalho E, Jansson PA, Axelsen M, Eriksson JW, Huang X, Groop L, Rondinone C, Sjöström L, Smith U.
    FASEB J. 1999:13(15):2173-8.
    Web of Science® citations 95
  39. Ebeling P, Jansson PA, Smith U, Lalli C, Bolli GB, Koivisto VA.
    Diabetes Care 1997:20(8):1287-9.
    Web of Science® citations 89
  40. Jansson PA, Krogstad AL, Lönnroth P.
    Am J Physiol. 1996:271(1 Pt 1):E138-42.
    Web of Science® citations 14
  41. Jansson PA, Gudbjörnsdóttir HS, Andersson OK, Lönnroth PN.
    Diabetes Care 1996:19(2):160-4.
    Web of Science® citations 24
  42. Jansson PA, Smith U, Lönnroth P.
    Eur J Clin Invest. 1995:25(8):584-9.
    Web of Science® citations 13
  43. Jansson PA, Larsson A, Smith U, Lönnroth P.
    J Clin Invest. 1994:93(1):240-6.
    Web of Science® citations 103
  44. Jansson PA, Veneman T, Nurjhan N, Gerich J.
    Life Sci. 1994:54(21):1621-4.
    Web of Science® citations 42
  45. Jansson PA, Larsson A, Smith U, Lönnroth P.
    J Clin Invest. 1992:89(5):1610-7.
    Web of Science® citations 158
  46. Jansson PA, Smith U, Lönnroth P.
    Diabetologia 1990:33(4):253-6.
    Web of Science® citations 120
  47. Jansson PA, Smith U, Lönnroth P.
    Am J Physiol. 1990:258(6 Pt 1):E918-22.
    Web of Science® citations 91

Scientific publications

1. Lönnroth P, Jansson P-A, Smith U: A microdialysis method allowing characterization of intercellular water space in humans. Am J Physiol 1987:253:E228-E231.
2. Jansson P-A, Fowelin J, Smith U, Lönnroth P: Characterization by microdialysis of intercellular glucose levels in subcutaneous tissue in humans. Am J Physiol 1988:255:E218-E220.
3. Lönnroth P, Jansson P-A, Fredholm BB, Smith U: Measurement by microdialysis of the intercellular adenosine concentration in the subcutaneous tissue in man. Am J Physiol 1989:256:E250-E255.
4. Jansson P-A, Smith U, Lönnroth P: Interstitial glycerol concentration measured by microdialysis in two subcutaneous regions in man. Am J Physiol 1990:258:E918-E922.
5. Jansson P-A, Smith U, Lönnroth P: Evidence for lactate production by human adipose tissue in vivo. Diabetologia 1990:33:253-6.
6. Jansson P-A, Larsson A, Smith U, Lönnroth P: Glycerol production in subcutaneous adipose tissue in lean and obese man. J Clin Invest 1992:89:1610-7.
7. Jansson P-A, Fowelin J, von Schenck H, Smith U, Lönnroth P: Measurement by microdialysis of the insulin concentration in the subcutaneous interstitial fluid. Diabetes 1993:42:1469-73.
8. Jansson P-A, Larsson A, Smith U, Lönnroth P: Lactate release from the subcutaneous tissue in lean and obese men. J Clin Invest 1994:93:240-6.
9. Jansson P-A, Veneman T, Nurjhan N, Gerich J: An improved method to calculate adipose tissue interstitial substrate recovery for microdialysis studies. Life Sci 1994:54:1621-4.
10. Pimenta W, Nurjhan N, Jansson P-A, Gerich J, Korytkowski M: Glycogen: Its mode of formation and contribution to hepatic glucose output in postabsorptive humans. Diabetologia 1994:37:697-703.
11. van der Merwe T, Eklund L, Jansson P-A, Lönnroth P: The effect of hyperglycemia on in vivo adipose tissue metabolism studied with microdialysis in type I diabetic subjects.
Diabetes 1994:43:866-70.
12. Jansson P-A, Lönnroth P: Comparison of two methods to assess the tissue/blood partition coefficient for xenon in subcutaneous adipose tissue in man. Clin Physiol 1995:15:47-55.
13 Karlsson A-K, Attvall S, Jansson P-A, Sullivan L, Lönnroth P: Influence of the sympathetic nervous system on insulin sensitivity and adipose tissue metabolism: A study in spinal cord-injured subjects. Metabolism 1995:44:52-8.
14. Jansson P-A, Smith U, Lönnroth P: Microdialysis assessment of adipose tissue metabolism in postabsorptive obese NIDDM subjects. Eur J Clin Invest 1995:25:584-9.
15. Eriksson JW, Jansson PA, Foley K, Lithell H. Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients. J Hypertens 1996;14(12):1469-75.
16. Jansson PA, Krogstad AL, Lönnroth P. Microdialysis measurements in skin: evidence for significant lactate release in healthy humans. Am J Physiol 1996;271(1 Pt 1):E138-42.
17. Jansson PA, Gudbjörnsdóttir HS, Andersson OK, Lönnroth PN. The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. Diabetes Care 1996;19(2):160-4.
18. Krogstad AL, Jansson PA, Gisslen P, Lönnroth P. Microdialysis methodology for the measurement of dermal interstitial fluid in humans. Br J Dermatol 1996;134(6):1005-12.
19. Stumvoll M, Perriello G, Nurjhan N, Bucci A, Welle S, Jansson PA, et al. Glutamine and alanine metabolism in NIDDM. Diabetes 1996;45(7):863-8.
20. Ebeling P, Jansson PA, Smith U, Lalli C, Bolli GB, Koivisto VA. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin. Diabetes Care 1997;20(8):1287-9.
21. Yu ZW, Jansson PA, Posner BI, Smith U, Eriksson JW. Peroxovanadate and insulin action in adipocytes from NIDDM patients. Evidence against a primary defect in tyrosine phosphorylation. Diabetologia 1997;40(10):1197-203.
22. Börsheim E, Jansson PA. Experiences of the 14C-ethanol technique for blood flow measurements in human subcutaneous adipose tissue. Life Sci 1998;62(11):967-72.
23. Jansson PA, Larsson A, Lönnroth PN. Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1998;28(10):813-8.
24. Axelsen M, Smith U, Eriksson JW, Taskinen MR, Jansson PA. Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes. Ann Intern Med 1999;131(1):27-31.
25. Carvalho E, Jansson PA, Axelsen M, Eriksson JW, Huang X, Groop L, et al. Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. Faseb J 1999;13(15):2173-8.
26. Eriksson JW, Smith U, Waagstein F, Wysocki M, Jansson PA. Glucose turnover and adipose tissue lipolysis are insulin-resistant in healthy relatives of type 2 diabetes patients: is cellular insulin resistance a secondary phenomenon? Diabetes 1999;48(8):1572-8.
27. Rizell M, Naredi P, Lindner P, Hellstrand K, Jansson PA. Validation of the internal reference technique for microdialysis measurements of interstitial histamine in the rat. Life Sci 1999;65(17):1765-71.
28. van der Merwe MT, Jansson PA, Crowther NJ, Boyd IH, Gray IP, Joffe BI, et al. Lactate and glycerol release from subcutaneous adipose tissue in black and white lean men. J Clin Endocrinol Metab 1999;84(8):2888-95.
29. Börsheim E, Lönnroth P, Knardahl S, Jansson PA. No difference in the lipolytic response to beta-adrenoceptor stimulation in situ but a delayed increase in adipose tissue blood flow in moderately obese compared with lean men in the postexercise period. Metabolism 2000;49(5):579-87.
30. Axelsson T, Jansson PA, Smith U, Eliasson B. Nicotine infusion acutely impairs insulin sensitivity in type 2 diabetic patients but not in healthy subjects. J Intern Med 2001;249(6):539-44.
31. Carvalho E, Jansson PA, Nagaev I, Wenthzel AM, Smith U. Insulin resistance with low cellular IRS-1 expression is also associated with low GLUT4 expression and impaired insulin-stimulated glucose transport. Faseb J 2001;15(6):1101-3.
32. Grahn A, Elmgren A, Åberg L, Svensson L, Jansson PA, Lönnroth P, et al. Determination of Lewis FUT3 gene mutations by PCR using sequence-specific primers enables efficient genotyping of clinical samples. Hum Mutat 2001;18(4):358-9.
33. Sandqvist MM, Eriksson JW, Jansson PA. Increased lactate release per fat cell in normoglycemic first-degree relatives of individuals with type 2 diabetes. Diabetes 2001;50(10):2344-8.
34. Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;25(5):869-75.
35. Jansson PA, Eliasson B, Lindmark S, Eriksson JW. Endocrine abnormalities in healthy first-degree relatives of type 2 diabetes patients--potential role of steroid hormones and leptin in the development of insulin resistance. Eur J Clin Invest 2002;32(3):172-8.
36. Rizell M, Naredi P, Lindner P, Hellstrand K, Sarno M, Jansson PA. Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat. Life Sci 2002;70(8):969-76.
37. Bonnier M, Lönnroth P, Gudbjörnsdóttir S, Attvall S, Jansson PA. Validation of a glucose-insulin-potassium infusion algorithm in hospitalized diabetic patients. J Intern Med 2003;253(2):189-93.
38. Brekke HK, Jansson PA, Mansson JE, Lenner RA. Lifestyle changes can be achieved through counseling and follow-up in first-degree relatives of patients with type 2 diabetes. J Am Diet Assoc 2003;103(7):835-43.
39. Hammarstedt A, Jansson PA, Wesslau C, Yang X, Smith U. Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. Biochem Biophys Res Commun 2003;301(2):578-82.
40. Pellmé F, Smith U, Funahashi T, Matsuzawa Y, Brekke H, Wiklund O, Taskinen MR, Jansson PA. Circulating adiponectin levels are reduced in non-obese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 2003;52(5):1182-6.
41. Johanson EH, Jansson PA, Lönn L, Matsuzawa Y, Funahashi T, Taskinen MR, et al. Fat distribution, lipid accumulation in the liver, and exercise capacity do not explain the insulin resistance in healthy males with a family history for type 2 diabetes. J Clin Endocrinol Metab 2003;88(9):4232-8.
42. Jansson PA, Pellmé F, Hammarstedt A, Sandqvist M, Brekke H, Caidahl K, et al. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. Faseb J 2003;17(11):1434-40.
43. Johanson EH, Jansson PA, Lönn L, Taskinen MR, Smith U, Axelsen M. Early alterations in the postprandial VLDL1 apoB-100 and apoB-48 metabolism in men with strong heredity for type 2 diabetes. J Intern Med. 2004;255(2):273-9.
44. Ahrén B, Landin-Olsson M, Jansson PA, Eriksson JW, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab, 2004;89(5):2078-84.
45. Sopasakis VR, Sandqvist M, Gustafson G, Hammarstedt A, Schmelz M, Yang X, Jansson PA, Smith U. High local concentrations and effects on differentiation implicate Interleukin-6 as a paracrine regulator. Obesity Research. 2004;12(3):454-60.
46. Yang X, Jansson P-A, Nagaev I, Jack M M, Carvalho E, Sunnerhagen K S , Cam M C , Cushman S W, Smith U. Evidence of impaired adipogenesis in insulin resistance. Biochem Biophys Res Commun,, 2004;317(4):1045-51.
47. Hammarstedt A, Sopasakis VR, Gogg S, Jansson PA, Smith U. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia. 2005;48(1):96-104.
48. Johanson EH, Jansson PA, Gustafson B, Sandqvist M, Taskinen MR, Smith U, Axelsen M. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes. Diabetes Metab Res Rev. 2005;21(4):376-81.
49. Brekke H, Lenner RA, Taskinen MR, Månsson JE, Funahashi T, Matsuzawa Y, Jansson PA. Lifestyle modification improves risk factors in type 2 diabetes relatives. Diabetes Res Clin Pract. 2005;68(1):18-28.
50. Sandqvist M, Nyberg G, Hammarstedt A, Klintland N, Gogg S, Caidahl K, Ahrén B, Smith U, Jansson PA. Low adipocyte IRS-1 protein expression is associated with an increased arterial stiffness in non-diabetic males. Atherosclerosis. 2005;180(1):119-25.
51. Brekke HK, Jansson PA, Lenner RA. Long-term (1- and 2-year) effects of lifestyle intervention in type 2 diabetes relatives. Diabetes Res Clin Pract. 2005;70(3):225-34.
52. Yang X, Jansson PA, Pellme F, Laakso M, Smith U. Effect of the interleukin-6 (-174) g/c promoter polymorphism on adiponectin and insulin sensitivity. Obes Res, 2005;13(5):813-7.
53. Dahlgren E, Gull B, Willen R, Sundler F, Rosen T, Jansson PA. Sertoli-Leydig cell tumour in a postmenopausal woman showing all facets of the insulin resistance syndrome (IRS).
Ups J Med Sci. 2005;110(3):233-6.
54. Hammarstedt A, Pihlajamaki J, Rotter Sopasakis V, Gogg S, Jansson PA, Laakso M, Smith U.Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab. 2006;91(3):1181-4.
55. Mobini R, Fu M, Jansson PA, Bergh CH, Scharin Tang M, Waagstein F, Andersson B.. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine.
Clin Sci (Lond). 2006;110(3):329-36.
56. Sandqvist M, Johanson EH, Ahren B, Axelsen M, Schmelz M, Smith U, Jansson PA. Postprandial interstitial insulin concentrations in type 2 diabetes relatives. Eur J Clin Invest. 2006;36(6):383-8.
57. Graham T, Yang Q, Bluher M, Hammarstedt A, Ciaraldi T, Henry R, Wason C, Oberbach A, Jansson PA, Smith U, Kahn B. Retinol-Binding Protein 4 and insulin resistance in lean and obese subjects and subjects with type 2 diabetes. N Engl J Med 2006;354:22-33.
58. Murdolo G, Hammarstedt A, Sandqvist M, Herder C, Smith U, Jansson PA. Monocyte chemoattractant protein-1 (MCP-1) in subcutaneous abdominal adipose tissue: characterization of interstitial concentration and regulation of gene expression by insulin. J Clin Endocrinol Metab 2007;92:2688-95.
59. Murdolo G, Kempf K, Hammarstedt A, Herder C, Smith U, Jansson PA. Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest. 2007;30(8):RC17-21.
60. Staiger H, Stancáková A, Zilinskaite J, Vänttinen M, Hansen T, Marini MA, Hammarstedt A, Jansson PA, Sesti G, Smith U, Pedersen O, Laakso M, Stefan N, Fritsche A, Häring HU. A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations: results from the EUGENE2 study. Diabetes. 2008;57(2):514-7.
61. Laakso M, Zilinskaite J, Hansen T, Boesgaard TW, Vänttinen M, Stancáková A, Jansson PA, Pellmé F, Holst JJ, Kuulasmaa T, Hribal ML, Sesti G, Stefan N, Fritsche A, Häring H, Pedersen O, Smith U; EUGENE2 Consortium. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia. 2008;51(3):502-11.
62. Stancáková A, Pihlajamäki J, Kuusisto J, Stefan N, Fritsche A, Häring H, Andreozzi F, Succurro E, Sesti G, Boesgaard TW, Hansen T, Pedersen O, Jansson PA, Hammarstedt A, Smith U, Laakso M; EUGENE2 Consortium. Single-nucleotide polymorphism rs7754840 of CDKAL1 is associated with impaired insulin secretion in nondiabetic offspring of type 2 diabetic subjects and in a large sample of men with normal glucose tolerance. J Clin Endocrinol Metab. 2008;93(5):1924-30.
63. Boesgaard TW, Zilinskaite J, Vänttinen M, Laakso M, Jansson PA, Hammarstedt A, Smith U, Stefan N, Fritsche A, Häring H, Hribal M, Sesti G, Zobel DP, Pedersen O, Hansen T; EUGENE 2 Consortium. The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients--the EUGENE2 study. Diabetologia. 2008;51(5):816-20.
64. Murdolo G, Sjöstrand M, Strindberg L, Gudbjörnsdóttir S, Lind L, Lönnroth P, Jansson PA.
Effects of Intrabrachial metacholine infusion on muscle capillary recruitment and forearm glucose uptake during physiological hyperinsulinemia in obese, insulin-resistant individuals. J Clin Endocrinol Metab. 2008;93(7):2764-73.
65. Murdolo G, Herder C, Wang Z, Rose B, Schmelz M, Jansson PA:
In situ profiling of adipokines in subcutaneous microdialysates from lean and obese individuals. Am J Physiol Endocrinol Metab 2008;295:E1095-105.
66. Eriksson JW, Jansson PA, Carlberg B, Hägg A, Kurland L, Svensson MK, Ahlström H, Ström C, Lönn L, Öjbrandt K, Johansson L, Lind L:
Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension 2008;52:1030-7.
67. Gogg S, Smith U, Jansson PA: Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothelial cells in type 2 diabetes - the role of endothelin-1.
Diabetes 2009;58:2238-45.
68. Boesgaard TW, Gjesing AP, Grarup N, Rutanen J, Jansson PA, Hribal ML, Sesti G, Fritsche A, Stefan N, Staiger H, Häring H, Smith U, Laakso M, Pedersen O, Hansen T; EUGENE 2 Consortium: Variant near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients – EUGENE 2 study. PLoS One 2009;4:e7326.
69. Murdolo G, Hammarstedt A, Schmelz M, Jansson PA, Smith U.
Acute hyperinsulinemia differentially regulates interstitial and circulating adiponectin oligomeric pattern in lean and insulin-resistant, obese individuals. J Clin Endocrinol Metab 2009;94:4508-16.
70. Boström P, Andersson L, Vind B, Håversen L, Rutberg M, Wickström Y, Larsson E, Jansson P-A, Svensson M, Brånemark R, Ling C, Beck-Nielsen H, Borén J, Højlund K, Olofsson S-O. The SNARE protein SNAP23 and the SNARE-interacting protein Munc18c in human skeletal muscle are implicated in insulin sensitivity. Diabetes 2010;59:1870-8.
71. Jansson P-A, Murdolo G, Sjögren L, Nyström B, Sjöstrand M, Strindberg L, Lönnroth P.
Phosphodiesterase-5 inhibition increases muscle capillary recruitment and forearm glucose uptake in type 2 diabetes patients. Diabetologia 2010;53:2205-8.
72.Sjöstrand M , Jansson P-A, Palming J, deSchoolmeester J, Gill D, Rees A, Sjögren L, Persson T, Eriksson J. Repeated Measurements of 11β-HSD-1 activity in Subcutaneous Adipose Tissue from Lean, Abdominally Obese and Type 2 diabetes subjects. Horm Metab Res 2010:42:798-802.
73.Palming J, Jansson P-A, Renström F, Elmgren A, Johansson A, Johansson L, Karlsson C, Lind L, Eriksson J. Hydrochlorothiazide compared to candesartan treatment increases adipose tissue gene expression and circulating levels of serum amyloid A in hypertensive patients. Horm Metab Res 2011:43:319-24.
74.Sandqvist M, Strindberg L, Lönnroth P, Jansson P-A. Impaired delivery of insulin to adipose tissue and skeletal muscle in obese women with postprandial hyperglycemia. J Clin Endocrinol Metab 2011:96:E1320-24. *
75.Svensson M, Jansson P-A, Persson A, Sjöstrand M, Eriksson J. Atropine improves insulin sensitivity in both lean and abdominally obese subjects. J Clin Endocrinol Metab 2011: 96:E1843-47.
76.Hribal ML, Presta I, Procopio T, Marini MA, Stancakova A, Kuusisto J, Andreozzi F, Hammarstedt A, Jansson P-A, Grarup N, Hansen T, Walker M, Stefan N, Fritsche A, Häring HU, Pedersen O, Smith U, Laakso M, Sesti G; Eugene2 Consortium. Glucose tolerance, insulin sensitivity and insulin release in European non-diabetic carriers of a polymorphism upstream of CDKN2A and CDKN2B. Diabetologia 2011:54:795-802.
77.Daka B, Jansson P-A, Rosén T, Larsson CA, Råstam L, Lindblad U. Inverse association between serum insulin and sex hormone-binding globulin in a population survey in Sweden. Endocr Connect 2013:2:18-22.
78.Hellgren MI, Petzold M, Björkelund C, Wedel H, Jansson P-A, Lindblad U. Feasibility of the FINDRISC questionnaire to identify individuals with impaired glucose tolerance in Swedish primary care. A cross-sectional population-based study. Diabet Med 2012:29:1501-5.
79.Dekker Nitert M, Dayeh T, Volkov P, Elgzyri T, Hall E, Nilsson E, Yang B, Lang S, Parikh H, Wessman Y, Weishaupt H, Attema J, Ländin M, Wierup N, Almgren P, Jansson P-A, Rönn T, Hansson O, Eriksson K-F, Groop L, Ling C. Impact of an exercise intervention on DNA methylation in skeletal muscle from first degree relatives of patients with type 2 diabetes. Diabetes 2012:61:3322-32.
80.Sjörs A, Jansson P-A, Eriksson JW, Jonsdottir H. Increased insulin secretion and decreased glucose concentrations, but not allostatic load, are associated with stress-related exhaustion in a clinical patient population. Stress 2013:16:24-33.
81.Murdolo G, Sjöstrand M, Strindberg L, Lönnroth P, Jansson P-A. The selective phosphodiesterase-5 inhibitor tadalafil induces microvascular and metabolic effects in type 2 diabetic postmenopausal females. J Clin Endocrinol Metab 2013:98:245-54. *
82.Ahlin S, Sjöholm K, Jacobson P, Andersson-Assarsson JC, Walley A, Tordjman J, Poitou C, Prifti E, Jansson P-A, Borén J, Sjöström L, Froguel P, Bergman RN, Carlsson LMS, Olsson B, Svensson P-A. Macrophage gene expression in adipose tissue is obesity-independently associated with insulin sensitivity and serum lipid levels. Obesity 2013:21:E571-6.
83.Daka B, Jansson P-A, Rosén T, Larsson C, Råstam L, Lindblad U. Low sex hormone-binding globulin is associated with hypertension: A cross sectional study in a Swedish population. BMC Cardiovasc Dis 2013:13:30.
84.Sandqvist M, Strindberg L, Lönnroth P, Jansson P-A. Decreased permeability surface area for glucose in obese women with postprandial hyperglycemia. No effect of phosphodiesterase-5 (PDE-5) inhibition. Horm Metab Res 2013:45:556-60.
85.Nilsson E, Jansson P-A, Perfilyev A, Volkov P, Pedersen M, Svensson MK, Poulsen P, Ribel-Madsen R, Pedersen NL, Almgren P, Fadista J, Rönn T, Klarlund-Pedersen B, Scheele C, Vaag A, Ling C. Altered DNA methylation and differential expression of genes influencing metabolism and inflammation in adipose tissue from subjects with type 2 diabetes. Diabetes 2014:63:2962-76.
86.Hellgren M, Daka B, Jansson P-A, Lindblad U, Larsson C. Insulin resistance predicts early cardiovascular morbidity in men without diabetes mellitus and this effect is modified by physical activity. Eur J Prev Cardiology 2014 [Epub ahead of print].
87.Hellgren M, Petzold M, Berteus-Forslund H, Wedel H, Jansson P-A, Lindblad U. Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance – a pilot study. Scand J Public Health 2014 [Epub ahead of print].
88.Hellgren M, Daka B, Jansson P-A, Lindblad U. Primary care screening for individuals with impaired glucose metabolism with focus on impaired glucose tolerance. Primary Care Diabetes 2014 [Epub ahead of print].
89.Hellgren MI, Larsson CA, Daka B, Petzold M, Jansson PA, Lindblad U. C-Reactive Protein Concentrations and Level of Physical Activity in Men and Women With Normal and Impaired Glucose Tolerance. A Cross-Sectional Population-Based Study in Sweden. J Phys Act Health 2015 Dec 21. [Epub ahead of print].
90.Daka B, Olausson J, Larsson CA, Hellgren MI, Råstam L, Jansson PA, Lindblad U. Circulating concentrations of endothelin-1 predict coronary heart disease in women but not in men: a longitudinal observational study in the Vara-Skövde Cohort. BMC Cardiovasc Disord 2015 Nov 14;15(1):146.
91.Sjögren L, Olausson J, Strindberg L, Mobini R, Fogelstrand P, Mattsson Hultén L, Jansson PA. Postprandial effects of the phosphodiesterase-5 inhibitor tadalafil in people with well-controlled Type 2 diabetes mellitus: a randomized controlled trial. Diabet Med 2015 [Epub ahead of print].
92.Daka B, Langer RD, Larsson CA, Rosén T, Jansson PA, Råstam L, Lindblad U. Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus. BMC Endocr Disord 2015:15:35.
93.Rönn T, Volkov P, Gillberg L, Kokosar M, Perfilyev A, Jacobsen AL, Jørgensen SW, Brøns C, Jansson PA, Eriksson KF, Pedersen O, Hansen T, Groop L, Stener-Victorin E, Vaag A, Nilsson E, Ling C. Impact of age, BMI and HbA1c levels on the genome-wide DNA methylation and mRNA expression patterns in human adipose tissue and identification of epigenetic biomarkers in blood. Hum Mol Genet 2015:24:3792-813.
94.Olausson J, Daka B, Hellgren M, Larsson CA, Petzold M, Lindblad U, Jansson PA. Endothelin-1 as a predictor of impaired glucose tolerance and type 2 diabetes – A longitudinal study in the Vara-Skövde cohort. Diab Res Clin Pract 2016 [Epub ahead of print].
95.Fryk E, Perman Sundelin J, Strindberg L, Pereira M, Federici M, Marx N, Nyström F, Schmelz M, Svensson P-A, Eriksson J, Borén J, Jansson P-A. Microdialysis and proteomics of the subcutaneous interstitial fluid reveals abundance of galectin-1 in type 2 diabetes patients. Metabolism 2016, accepted
96.Mobini R, Tremaroli V, Ståhlman M, Karlsson F, Levin M, Ljungberg M, Schmelz M, Berteus Forslund H, Perkins R, Bäckhed F, Jansson P-A. L. Reuteri DSM 17938 improves insulin sensitivity in type 2 diabetes patients on insulin therapy: a randomized controlled trial. J Clin Endocrinol Metab, submitted
97.Dayeh T, Tuomi T, Almgren P, Perfilyev A, Jansson P-A, Pihlajamäki J, de Mello V, Vaag A, Groop L, Nilsson E, Ling C. DNA methylation at ABCG1 and PHOSPHO1 in blood DNA is associated with future type 2 diabetes risk. Epigenetics, accepted.

Other publications

Avhandling:
Microdialysis of human subcutaneous tissue - A new technique to study fat cell meatbolism in situ. Gradualavhandling. Göteborgs Universitet, försvarad 3:e oktober 1991.

Bokkapitel, översiktsartiklar:
1. Lönnroth P, Jansson P-A, Smith U: Adipose tissue metabolism measured by microdialysis. In: Björntorp P, Rössner S (eds) Obesity in Europe 88, John Libbey, London, pp 209-14.
2. Jansson P-A, Smith U, Lönnroth P: Lactate production in subcutaneous adipose tissue in lean and obese man. In: Ailhaud G et al (eds) Obesity in Europe 91, John Libbey, London, pp 397-400
3. Lönnroth P, Jansson P-A: Microdialysis in human subcutaneous tissue. Progress in Obesity Research: 7, edited by Angel et al. John Libbey & Company Ltd 1996, pp 111-19.
4. Jansson P-A, Enerbäck S, Eriksson J, Elam M, Smith U: Insulin resistance and increased plasma leptin levels in healthy non-obese first degree relatives to NIDDM subjects: no relation to sympathetic nerve activity. In: Leptin the voice of adipose tissue, edited by W.F. Blum, W. Kiess, W. Rascher J.A. Barth Verlag, Heidelberg. Leipzig 1997, pp 269-74.
5. Smith U, Axelsen M, Carvalho E, Eliasson B, Jansson P-A, Wesslau C: Insulin signalling and action in fat cells – Associations with insulin resistance and type 2 diabetes. Ann NY Acad Sci, 1999;892:119-26.
6. Jansson P-A. Endothelial dysfunction in insulin resistance and diabetes. Review. J Intern Med 2007; 262:173-83.
7. Andersson CX, Hammarstedt A, Jansson P-A, Smith U. In, Metabolic Syndrome, edited by Hansen/Bray. Chapter III: Causal mechanisms of insulin action in muscle fat and liver in the metabolic syndrome. Insulin signaling in adipocytes and the role of inflammation.

Work experience

WorkplaceDegree of EmploymentStartedEnded
Statligt - Universitet - Göteborgs universitet - Sahlgrenska akademin - Institutionen för medicin - Avdelningen för molekylär och klinisk medicin workplace verified by Sahlgrenska Akademin on 2017-04-05
50% 2006
Kommun - Enskilda kommuner - Göteborg Show info
Sedan 2006 anställd som forskare 50% vid Göteborgs Universitet

50% 1987

Ansvarig lärare för diabetesundervisningen på läkarprogrammet vid Göteborgs universitet 1999 - 2010

Föreläser regelbundet för medicinstuderande och andra personalkategorier på Sahlgrenska Universitetssjukhuset. Prof emeritus Ove Andersson referensperson i egenskap av ansvarig för kursen i invärtesmedicin under många år.

Medverkat till framtagande av informationsskrift om diabetesbehandling i samarbete med läkemedelsindustrin.

15 hp i högskolepedagogik

Har anslag från Vetenskapsrådet sedan 2005, Svenska Diabetesförbundet och vid två tillfällen projektanslag från European Foundation for the Study of Diabetes på 100000 Euro vardera.
Flera samarbetsprojekt med R&D-enheten vid Astra Zeneca AB.

Varit fakultetsopponent nio gånger.

Ansvarig för nationella läkemedelsprövningar.

Arrangör av ett endotelsymposium med ekonomiskt stöd från Novo Nordisk.

Medicinsk konsult 20% åt Astra Zeneca AB 2007-2008.

Units that user is associated with

Additional information

A. Professional preparation
1990 licensed physician, 1994 board certified in general internal medicine and 1998 board certified in endocrine diseases
1991PhD, University of Gothenburg. Thesis: “Microdialysis of human subcutaneous tissue – A new technique to study fat cell metabolism in situ”
Supervisor: Prof. Peter Lönnroth
1992-1993 post doc, The Whittier Institute for Diabetes Research, La Jolla, San Diego, USA. Host: Prof John Gerich
1996associate professor of general internal medicine, University of Gothenburg
2011 appointed university hospital senior consultant, Department of Medicine, Sahlgrenska University Hospital, Gothenburg

B. Appointments
2001 senior consultant and senior lecturer (20% research Oct 2001- Oct 2004), Department of Medicine, Sahlgrenska University Hospital, Gothenburg
2004 - 2005 adjunct professor in clinical and experimental diabetes research, University of Gothenburg
2006 - 2011 researcher 50% (metabol molekylär reglering) at the Swedish Research Council
2012 – 2014 researcher 50% at the University of Gothenburg
2010 - medical adviser at Gothia Forum, Sahlgrenska University Hospital
2014 – professor at the University of Gothenburg

C. Tutoring experience
Main supervisor of PhD students: 2005 Madeléne Sandqvist MD; 2015 Lovisa Sjögren MD; 2015 Josefin Olausson, M Sc Molecular Biology
Co-supervisor of PhD students: 2004 Hilde Brekke, Dep of Clinical Nutrition, University of Gothenburg; Feb 2014 Bledar Daka, MD and March 2014 Margareta Leonardsson-Hellgren, MD, Dep of Public Health and Community Medicine, University of Gothenburg

D. Networks in academia and industry
Established network of national and international collaboration partners as indicated by the publication list.
2004 – 2006 member of the Galileo group of upcoming key opinion leaders in Europe. This opportunity generated a great network in academia.

E. Entreprenurial achievements
Nothing of relevance

F. Other merits of relevance
Supervisor of post-doc: Giuseppe Murdolo MD, University of Perugia, Italy

Faculty Opponent: April 2005 (dr Thomas Nyström, KI), October 2005 (dr Patrik Löfgren, KI), October 2006 (dr Jeanette Kuhl, KI), March 2008 (dr Simona Chisalita, LiU), September 2009 (Fil cand Lise Wegener, Steno Diabetes Center), Fenruary 2010 (Fil cand Maj Sundbom, KI), November 2010 (dr Alexey Shemyakin, KI), April 2014 (Fil cand Linnea Carlsson, KI) and June 2017 (Oskar Kövamees, KI).

Ad hoc reviewer: Diabetologia, Diabetes, American Journal of Physiology, FASEB Journal, Diabetic Medicine, European Journal of Endocrinology, Hormone and Metabolic Research, International Journal of Obesity, Molecular and Cellular Endocrinology

Distinctions: Recipient of scholarship from Marabou Sweden AB and Odd Fellow Gothenburg for a post doc in Prof John Gerichs Lab, 1992 – 1993

Commissions of trust: Previously evaluator at National Research Councils in Portugal and Italy. 2008 member of Programme Committee for European Association for Study of Diabetes (EASD) annual meeting in Rome; 2008 - member of the “Docentur-committee at the Sahlgrenska Academy”; 2009 – evaluator of grant applications in panel B at the Medical Research Council; 2014-16 – evaluator of grant applications and member of the scientific board at the Swedish Diabetes Foundation; 2014-16 - external evaluator of grant applications to ALF in Stockholm County; 2014-16 - appointed expert evaluator of applications to the regional ethical review board (EPN) in Gothenburg

Six times chair person in oral and poster sessions at the EASD meetings
Three times invited speaker to national and international meetings

Scientific production: Author of ca 100 original papers and 2 reviews

Good Clinical Practice: 2008 one day course in GCP at Astra Zeneca. From 2010-2014 lecturer in GCP at Gothia Forum.

Gothenburg in May 2017

Per-Anders Jansson, MD, PhD

Information is reliable | updated 2017-12-05 by Per-Anders Jansson |

User account for Per-Anders Jansson, from FoU i Sverige
http://www.researchweb.org/is/sverige/user/html/3585